What is the significance of the curtain sign in myasthenia gravis (Myasthenia Gravis, MG)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The curtain sign is a significant diagnostic feature of myasthenia gravis, indicating asymmetric ptosis that worsens with sustained upward gaze and may improve when the other eyelid is manually lifted, and its early recognition can lead to prompt diagnosis and management of the disease. This occurs because in myasthenia gravis, there is an autoimmune attack on acetylcholine receptors at the neuromuscular junction, causing muscle fatigue and weakness, particularly in ocular muscles 1. When one eyelid is manually lifted, the neural input to both eyelids decreases due to shared innervation pathways, reducing the demand on the affected muscle and temporarily improving the ptosis on the other side.

Clinical Significance

The curtain sign is a useful clinical diagnostic feature of myasthenia gravis, especially in patients presenting with fluctuating ocular symptoms. Other diagnostic tests include acetylcholine receptor antibody testing, repetitive nerve stimulation, and the edrophonium (Tensilon) test.

Treatment Options

Treatment typically involves acetylcholinesterase inhibitors like pyridostigmine (30-60mg orally every 4-6 hours), immunosuppressants such as prednisone or azathioprine, and in some cases, thymectomy 1. For some patients, various forms of immunosuppressive therapy with azathioprine, which is known to be effective, and other agents under current investigation such as efgartigimod alfa-fcab may be offered by treating neurologists. Efgartigimod alfa-fcab has recently been FDA approved for patients who test positive for the anti-acetylcholine receptor 1.

Management Considerations

Diplopia and strabismus are highly variable and not readily remedied with prisms. Remission or stabilization of the disease is often possible after 2 to 3 years of treatment, and at that point surgical intervention for strabismus may be considered if desired or if prism use is insufficient 1. Care is indicated in the use of anesthetic agents given any evidence of associated weakness of the respiratory muscles. Surgical management, with and without the use of adjustable sutures, has met with modest success in cases where there is a stabilized primary deviation, sometimes exacerbated by fatigue 1.

From the Research

Significance of the Curtain Sign in Myasthenia Gravis

There is no direct information available in the provided studies regarding the significance of the curtain sign in Myasthenia Gravis (MG).

Available Information on Myasthenia Gravis

  • Myasthenia Gravis is a rare autoimmune disease characterized by exertion-induced muscle weakness that can lead to potentially life-threatening myasthenic crises 2.
  • The disease is caused by detectable antibodies directed against specific postsynaptic structures of the neuromuscular junction 2.
  • Treatment options for MG include symptomatic treatment with acetylcholinesterase inhibitors, disease-modifying treatment with steroids, steroid-sparing immunosuppressants, and thymectomy 2, 3, 4, 5.
  • Recent advances in the understanding of the pathophysiology of MG have led to new treatment options targeting B or T cells, the complement cascade, the neonatal Fc receptor, or cytokines 5.

Limitations of Current Research

  • There are no research papers available in the provided studies to assist in answering the question about the significance of the curtain sign in Myasthenia Gravis.
  • Further research is needed to understand the specific aspects of MG, including the curtain sign, and to improve treatment options for patients with this condition.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2025

Research

Treatment of myasthenia gravis: focus on pyridostigmine.

Clinical drug investigation, 2011

Research

Myasthenia gravis-Pathophysiology, diagnosis, and treatment.

Handbook of clinical neurology, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.